Sanofi-Synthélabo was a major pharmaceutical company formed in 2004 through the merger of Sanofi and Synthélabo. The company focused on research, development, and marketing of prescription medications, particularly in areas such as cardiovascular health, diabetes, and oncology. In 2006, Sanofi-Synthélabo rebranded itself simply as Sanofi, streamlining its identity in the global pharmaceutical market. The company has since continued to expand its portfolio and invest in innovative treatments, contributing significantly to healthcare advancements worldwide.